Ralph Herbst

“AskBio’s contribution to genetic medicine is remarkable. From pioneering research to the clinical advancement of therapeutics, we will continue to lead the way.”

Ralph Herbst

Chief Strategy Officer

Ralph Herbst formally joined AskBio in June 2023 and serves as Chief Strategy Officer. He began contributing to various strategic initiatives in 2022 as a trusted colleague of the executive team. Coming from Bayer, AskBio’s parent company, Ralph is integral in setting the direction for the company’s technology platform, establishing clinical priorities, and executing the strategy. An inspiring and authentic senior executive with an entrepreneurial mind, Ralph has a significant track record of delivering growth and bottom-line results.

Most recently, Ralph was the Head of Strategy Implementation at Bayer’s Cell & Gene Therapy (CGT) Platform. In this role, Ralph expanded CGT capabilities with internal teams and resources and developed various strategic collaborations, while playing a key role in securing licensing agreements and completing technology acquisitions. Ralph also played a leading role in Bayer’s acquisitions of BlueRock Therapeutics LP and AskBio, cornerstones of Bayer’s CGT Platform. His other roles at Bayer included Head of Cell & Gene Therapy Activator and Vice President of Pharmaceutical Technical Operations. Ralph also spent over six years with Covestro, one of the world’s top polymer materials manufacturers, where he rose to Vice President of New Markets and helped launch new technologies and products in Europe, Middle East, Brazil, China, and India.

Ralph received an undergraduate degree from Dartmouth College, an MBA from Rotterdam School of Management at Erasmus University, and a Master of Science from RWTH Aachen University, one of Europe’s leading institutions for science, technology, and research.